Neuroepidemiology by Sejvar, James J. et al.
Population Incidence of Guillain-Barré Syndrome: A Systematic 
Review and Meta-Analysis
James J. Sejvar, Andrew L. Baughman, Matthew Wise, and Oliver W. Morgan
Division of High-Consequence Pathogens and Pathology and Division of Vector-Borne Infectious 
Diseases, Centers for Disease Control and Prevention, Atlanta, Ga., USA
Abstract
Population incidence of Guillain-Barré syndrome (GBS) is required to assess changes in GBS 
epidemiology, but published estimates of GBS incidence vary greatly depending on case 
ascertainment, definitions, and sample size. We performed a meta-analysis of articles on GBS 
incidence by searching Medline (1966–2009), Embase (1988–2009), Cinahl (1981–2009) and 
CABI (1973–2009) as well as article bibliographies. We included studies from North America and 
Europe with at least 20 cases, and used population-based data, subject matter experts to confirm 
GBS diagnosis, and an accepted GBS case definition. With these data, we fitted a random-effects 
negative binomial regression model to estimate age-specific GBS incidence. Of 1,683 
nonduplicate citations, 16 met the inclusion criteria, which produced 1,643 cases and 152.7 
million person-years of follow-up. GBS incidence increased by 20% for every 10-year increase in 
age; the risk of GBS was higher for males than females. The regression equation for calculating 
the average GBS rate per 100,000 person-years as a function of age in years was exp[−12.0771 
+ 0.01813(age in years)] × 100,000. Our findings provide a robust estimate of background GBS 
incidence in Western countries. Our regression model may be used in comparable populations to 
estimate the background age-specific rate of GBS incidence for future studies.
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Introduction
Guillain-Barré syndrome (GBS) is a condition characterized by the acute or subacute onset 
of varying degrees of weakness in limbs or cranial nerve-innervated muscles, associated 
decreased or absent deep tendon reflexes, and a characteristic profile in the cerebrospinal 
fluid and electrodiagnostic studies [1]. The underlying etiology and pathophysiology of GBS 
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are not completely understood [2], but it is thought to be an immune-mediated process, 
resulting from the generation of autoimmune antibodies and inflammatory cells that cross-
react with epitopes on peripheral nerves and roots, leading to demyelination, axonal damage 
or both [3]. This immune response is thought to be initiated in response to a variety of 
antigenic stimuli, such as viral or bacterial infection, particularly Campylobacter jejuni [4, 
5]. Vaccines are another antigenic stimulus for which potential associations with GBS have 
been reported, including formulations of Semple rabies vaccine, tetanus toxoid vaccine, and 
some formulations of influenza vaccine [6–8]. With rare exceptions, the biological or 
epidemiological evidence for a causal association between GBS and antecedent infections or 
vaccination is equivocal.
A firm measure of the incidence of GBS is increasingly important. GBS appears to be the 
most frequent cause of nonpoliovirus acute flaccid paralysis worldwide; however, accurate 
estimates of GBS incidence are unknown for many countries. Additionally, the rare 
association of various vaccines with GBS has made this syndrome an important focus of 
vaccine safety monitoring [9]. Assessing the presence, magnitude, and attributable risk of 
vaccine-associated GBS requires reliable age-specific incidence estimates. However, 
reported estimates of GBS incidence for all ages combined vary from 0.16 to 3.0 per 
100,000 person-years [10]. Some of the variability may be due to true differences in GBS 
incidence; for example, GBS incidence is thought to be higher in parts of Asia [11]. 
However, even in Europe and North America where most studies have been conducted, 
reported GBS incidence varies considerably [10]. Some variability is likely artifactual 
resulting from different case ascertainment methods, case definitions, and case inclusion 
criteria. A recent comprehensive systematic literature review summarized data from articles 
worldwide describing the epidemiology of GBS, including trends in incidence [10]. 
However, the expansive nature of this review included all articles irrespective of 
methodology, precluding direct comparisons of incidence estimates.
Here we present findings of a systematic review and meta-analysis of published studies 
reporting GBS incidence to obtain the most reliable estimates of population-based age-
specific incidence of GBS in North America and Europe.
Materials and Methods
Search Strategy
We searched for published work in any language recorded in Medline (January 1, 1966 to 
December 28, 2009), Embase (1988 to December 28, 2009), Cinahl (1981 to December 28, 
2009) and CABI (1973 to December 28, 2009). For searching databases, we used the 
following key words: ‘Polyradiculoneuropathy’, ‘Incidence’, ‘Epidemiology’, ‘Guillain-
Barré Syndrome’, ‘Immunization’, ‘Vaccination’, ‘Campylobacter’, and ‘Respiratory Tract 
Infections’ (Appendix). We also searched the reference lists of articles selected for full-text 
review for additional references.
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Selection Criteria
We selected studies based upon the following criteria: population based (cases were 
identified from a well-defined enumerated population); case finding was either prospective, 
retrospective, or a combination of both; at least 20 cases were identified; GBS cases were 
confirmed by subject matter experts (neurologists) from prospective patient evaluation, 
medical chart review, or both, and a clear and widely accepted case definition for GBS was 
used [e.g. National Institute of Neurological and Communicative Disorders and Stroke 
definition (NINCDS) [12], the case definition developed by Asbury and Cornblath [13], or 
the Brighton Collaboration [14] criteria]. We excluded studies that were not population 
based, or which depended upon administrative medical codes only (e.g. International 
Classification of Diseases codes) to identify cases. We limited the assessment to studies 
conducted in North America and Europe, because incidence of GBS in many parts of the 
world is not known, and some evidence suggests that the epidemiology of GBS may be 
substantially different in other regions.
Study Selection and Data Collection
Two investigators (J.J.S., O.W.M.) independently reviewed the title and abstract of all 
citations identified by the initial search strategy and excluded citations that clearly did not 
meet the inclusion criteria. We retrieved the full text of the remaining studies and both 
investigators reviewed each study to assess whether it met the inclusion criteria. When 
reviewers disagreed or were uncertain about the suitability of a study, a third investigator 
(M.W.) reviewed the paper and all investigators arrived at a consensus by discussion. One 
investigator, a board-certified neurologist (J.J.S.), extracted the following data from studies 
that met the inclusion criteria: study design, case ascertainment method, case definition 
used, study period, number of GBS cases identified (crude and age-specific), denominators 
(crude and age-specific), reported GBS incidence, and perceived study limitations. These 
data were verified by a second investigator (M.W.). When papers did not report the 
numerator and denominator used to calculate rates or only presented age-specific rates 
graphically, we attempted to contact the study authors for this information.
Statistical Analysis
For each study that reported age-specific incidence rates of GBS, we plotted the rate versus 
the midpoint of the reported age group and superimposed the plots on one graph for 
comparison. Because the oldest age group was open-ended in all of the studies, we assigned 
the median age for these groups using publicly available vital statistics data from the country 
in which the assessment was performed. For these assignments, we used data from the 
geographic area and time period that most closely matched each study population.
We fit random-effects Poisson and negative binomial regression models to the age-specific 
data. Models that included age as a continuous variable with a random effect for the 
intercept, slope, or both were explored [15]. Six of the 13 studies reported information to 
calculate age-specific rates of GBS by sex. For these 6 studies, we fit the same regression 
model used for the 13 studies overall, with the addition of the effect of sex.
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All regression models were fit using the NLMIXED procedure in SAS version 9.2. We used 
the results from the negative binomial regression model to derive an average rate of GBS for 
9 successive 10-year age groups (0–9, 10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79, 
80–89 years). For each estimated rate, we calculated a 95% prediction interval, which 
measures the uncertainty of the estimated rate for a randomly selected study by 
incorporating the between-study variability assumed by the model [16].
Results
We identified 1,879 citations from the database search, of which 1,683 citations were unique 
(i.e. nonduplicate) (fig. 1). After reviewing the titles and abstracts, we discarded 1,637 
citations (97%) that clearly did not meet the inclusion criteria for this review. We examined 
the full text of the remaining 46 articles in detail, of which 30 did not meet the inclusion 
criteria: 15 did not use a clear and widely accepted case definition or did not use subject 
matter experts to confirm the diagnosis of GBS; 8 were not population based, and 7 reported 
data that were substantially or wholly reported by other articles also selected for review. We 
did not identify additional studies that met the inclusion criteria from searching reference 
lists. Our final selection included 16 articles that met the inclusion criteria for this review [8, 
17–31], of which 13 have sufficient data to be included in the meta-analysis [8, 17, 18, 20–
27, 29, 31].
The selected articles reported data from Canada (n = 1), England (n = 2), Italy (n = 5), The 
Netherlands (n = 1), Spain (n = 4), Sweden (n = 1), and the United States (n = 2) (table 1). 
The mean study duration was 15 months (range, 4 months to 45 years) and the study period 
ranged from 1935 to 2002. Eight studies used prospective case identification, 6 retrospective 
case identification, and 2 studies both prospective and retrospective case identification. For 
GBS case definition, 12 studies (75%) applied the NINCDS criteria [12], 2 the criteria by 
Asbury and Cornblath [13], and 1 the Brighton Collaboration definition [14] (table 1). The 
study by Schonberger et al. [8] did not use a well-defined case definition; however, these 
data were rigorously reviewed several years later by Langmuir et al. [32], who found that 
91% of cases had sufficient data to be classified as having GBS. We included the article by 
Schonberger et al. [8] in preference to the article by Langmuir et al. [32] because it reported 
age-specific rates of GBS in the US population that did not receive the 1976 swine influenza 
vaccine, which we considered to be the background rate of GBS.
Of the 13 studies included in the meta-analysis, the number of cases ranged from 33 to 418 
(median, 81) (table 2). The number of age groups for which rates were reported ranged from 
3 to 9 (median, 7). Five articles presented both case counts and denominators [17, 18, 20, 22, 
25]; 5 articles presented case counts and rates [8, 24, 27, 29, 31]; 1 study provided only rates 
and we obtained case counts from the authors [21]; 1 study published only the rates in a line 
graph and we obtained publicly available census data to generate case counts and 
denominators [23], and 1 study published only the rates in a histogram and we obtained case 
counts and denominators from the authors [26].
The reported crude incidence ranged from 0.81 to 1.89 (median, 1.11) cases per 100,000 
person-years (table 2). Among the 13 studies, the rate of GBS increased exponentially with 
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age, with increasing variation in the rates from the younger to the older age groups (fig. 2a). 
The range of age-specific incidence rates increased from roughly 3-fold differences between 
studies in the younger age groups to as much as 10-fold differences in the older age groups.
The meta-analysis included 1,643 cases and 152.7 million person-years of follow-up. The 
random-effects negative binomial regression model fit the data better than the random-
effects Poisson model (likelihood ratio test, p < 0.01). The best-fitting negative binomial 
regression model included age as a continuous variable with a single random effect for the 
slope parameter to represent deviation of each study’s true effect from the overall mean 
effect. Results from this model suggested a 20% increase in the average GBS rate for every 
10-year increase in age (fig. 3a). For persons aged 0–90 years in North America and Europe, 
the regression equation for calculating the average GBS rate per 100,000 person-years as a 
function of age in years was exp[−12.0771 + 0.01813(age in years)] × 100,000.
The age-specific GBS rate increased from 0.62 cases per 100,000 person-years among 0- to 
9-year-olds to 2.66 cases per 100,000 person-years among 80- to 89-year-olds (table 3). The 
prediction intervals became wider with increasing age, especially after about age 70 years 
(fig. 3a).
Age-specific rates of GBS by sex revealed higher rates for males than females (fig. 2b, c). 
This pattern was confirmed by the model-based estimates (fig. 3b), which suggested a 
relative risk for males of 1.78 (95% CI, 1.36–2.33). For the calculation of age-specific rates 
of GBS by sex, the regression equations were exp[−12.4038 + 0.01914(age in years) 
+ 0.5777] × 100,000 for males and exp[−12.4038 + 0.01914(age in years)] × 100,000 for 
females.
Discussion
GBS is an uncommon disease and individual studies frequently lack sufficient numbers of 
cases to make reliable age-specific incidence estimates. Our meta-analysis of high-quality 
population-based published studies provides a robust estimate of average age-specific GBS 
incidence in North America and Europe. A regression model based on data combined from 
the studies showed an exponential increase in GBS incidence from 0.62 to 2.66 per 100,000 
person-years across all age groups. The prediction intervals for the estimated age-specific 
GBS incidence rates suggested that there was increasing uncertainty in the rates as age 
increased. This increasing variability in the GBS rate with age assumed by the regression 
model was consistent with the pattern of increased variation in observed incidence rates with 
age.
Differences in age-specific incidence rates across different study areas may be due to the 
application of case definitions rather than a true difference in the epidemiology of GBS. 
Although most of the studies included in our review used the same NINCDS criteria, GBS 
case definitions are syndrome-based, and their application depends on interpretation of 
clinical observations. Even though invasive tests such as lumbar puncture and 
electrodiagnostic studies can increase the level of diagnostic certainty, there is no biological 
marker to reliably diagnose GBS. Nevertheless, the application of syndrome-based case 
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definitions utilizing expert neurologist chart review is superior to relying on administrative 
data such as hospital discharge (International Classification of Diseases) codes, which are 
less specific and often overestimate true incidence [33, 34].
Observed rates in the studies were generally close to predicted rates derived from our 
regression model. In several studies, however, observed rates for the youngest or oldest age 
groups deviated significantly from predicted rates. There may be several reasons for these 
discrepancies. GBS is more difficult to diagnose in younger age groups, especially in 
pediatric patients, and varying rates in some study areas may reflect diagnostic uncertainty 
and either over- or underdiagnosis of GBS in younger patients [35, 36]. The lower incidence 
of GBS in older age groups may reflect a survivor bias, in which individuals surviving into 
their 80s and 90s are less likely to develop GBS, although there is no substantiated 
biological basis for this hypothesis.
Our assessment found a significantly higher risk of GBS among males, a finding that has 
been consistently demonstrated in published studies. The male predominance in GBS differs 
from that of most other autoimmune diseases such as multiple sclerosis and systemic lupus 
erythematosus, which frequently demonstrate higher rates in females [37, 38]. The reason 
for the higher risk of GBS in males is unknown.
Our study has several limitations. We only included data from published studies. However, 
unpublished sources of GBS incidence tend to be from administrative databases 
(International Classification of Diseases codes) and so would not be eligible for inclusion in 
the review. We focused our review on populations from North America and Europe, for 
which the largest number and most carefully conducted studies are available. However, the 
epidemiology of GBS may vary globally and our regression model for calculating age-
specific rates may not be applicable to all regions. Of the 13 studies included in our meta-
analysis, 8 were from Italy or Spain [17, 18, 21, 23–25, 27, 29]. However, we did not find 
any striking difference in GBS incidence between these and other countries that we 
included. We were unable to contact authors of 3 articles that met our eligibility criteria but 
for which we had insufficient data to be included in the meta-analysis [19, 28, 30]. 
Exclusion of these articles was unlikely to have changed our modeled incidence estimates as 
their reported crude incidence was 0.92 (n = 109), 1.2 (n = 79), and 1.18 (n = 476) per 
100,000 person-years, which fell within the range of the crude incidence in the 13 studies 
included in our meta-analysis.
Our findings provide a robust estimate of background GBS incidence. In light of the 
increasing variability in the background GBS incidence with age, future studies assessing 
the effects of potential risk factors need to provide carefully determined background rates, 
particularly in the oldest age groups. Investigators can use our model of the increase of GBS 
incidence across age groups for assessing changes of GBS incidence following 
immunizations, infections, or putative causal exposures.
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Appendix
Database Search Strategies
Medline
1. exp Polyradiculoneuropathy/
2. exp Incidence/
3. 1 and 2
4. exp Epidemiology/
5. 1 and 4
6. exp Guillain-Barre Syndrome/
7. exp Immunization/
8. 6 and 7
9. exp Vaccination/
10. 6 and 9
11. exp Campylobacter/
12. 6 and 11 and incidence.ti,ab.
13. exp Respiratory Tract Infections/
14. 6 and 13
15. 6 and rate.ti,ab.
16. 6 and influenza.ti,ab. 3 or 5 or 8 or 10 or 12 or 14 or 16
Embase
1. exp Polyradiculoneuropathy/
2. exp Incidence/
3. 1 and 2
4. exp Epidemiology/
5. 1 and 4
6. exp Guillain-Barre Syndrome/
7. exp Immunization/
8. 6 and 7
9. exp Vaccination/
10. 6 and 9
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11. exp Campylobacter/
12. 6 and 11 and incidence.ti,ab.
13. exp Respiratory Tract Infections/
14. 6 and 13
15. 6 and rate.ti,ab.
16. 6 and influenza.ti,ab.
17. 3 or 5 or 8 or 10 or 12 or 14 or 16
Cinahl
S2 (guillain-barre syndrome and (immunization or vaccination or (campylobacter and 
incidence) or respiratory tract infections or rate or influenza))
S1 (polyradiculoneuropathy and (incidence or epidemiology))
S3 (s1 or s2)
CABI
(((guillain-barre syndrome) AND (influenza))) OR (((guillain-barre syndrome) AND (rate))) 
OR (((guillain-barre syndrome) AND (respiratory tract infections))) OR (((guillain-barre 
syndrome) AND (campylobacter AND incidence))) OR (((guillain-barre syndrome) AND 
(immunization OR vaccination))) OR (((polyradiculoneuropathy) AND (incidence OR 
epidemiology)))
(guillain-barre syndrome) AND (influenza)
(guillain-barre syndrome) AND (rate)
(guillain-barre syndrome) AND (respiratory tract infections)
(guillain-barre syndrome) AND (campylobacter AND incidence)
(guillain-barre syndrome) AND (immunization OR vaccination)
(polyradiculoneuropathy) AND (incidence OR epidemiology)
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Fig. 1. 
Study selection.
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Fig. 2. 
a Plot of age-specific incidence rate of GBS per 100,000 person-years versus age in years, 
for 13 published studies. b Plot of age-specific incidence rate of GBS per 100,000 person-
years versus age in years, for 6 published studies that provided rates in males. c Plot of age-
specific incidence rate of GBS per 100,000 person-years versus age in years, for 6 published 
studies that provided rates in females.
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Fig. 3. 
a Plot of average age-specific incidence rate of GBS per 100,000 person-years versus age in 
years based on regression analysis of 13 published studies, with pointwise 95% prediction 
intervals (dashed lines) and observed rates (bubbles proportional to the number of person-
years). b Plot of average age-specific incidence rate of GBS per 100,000 person-years versus 
age in years based on regression analysis of 6 published studies that provided rates by sex 
(males: long dashed lines, females: short dashed lines).
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Table 3
Estimated rate of GBS by age group based on regression analysis of 13 studies, and estimated rate of GBS by 
age group and sex based on regression analysis of 6 studies
Age group
years
Mid-point
years
R ate per 100,000 person-years (95% PI)
total (n = 13) males (n = 6) females (n = 6)
0–9 5 0.62 (0.52–0.75) 0.80 (0.59–1.10) 0.45 (0.32–0.64)
10–19 15 0.75 (0.60–0.92) 0.97 (0.72–1.31) 0.55 (0.39–0.76)
20–29 25 0.90 (0.67–1.19) 1.18 (0.86–1.61) 0.66 (0.47–0.93)
30–39 35 1.07 (0.74–1.56) 1.43 (0.99–2.06) 0.80 (0.54–1.18)
40–49 45 1.29 (0.80–2.06) 1.73 (1.12–2.68) 0.97 (0.62–1.53)
50–59 55 1.54 (0.87–2.74) 2.09 (1.24–3.54) 1.18 (0.69–2.01)
60–69 65 1.85 (0.94–3.64) 2.54 (1.37–4.70) 1.42 (0.76–2.66)
70–79 75 2.22 (1.01–4.86) 3.07 (1.50–6.27) 1.72 (0.84–3.54)
80–89 85 2.66 (1.09–6.48) 3.72 (1.65–8.40) 2.09 (0.92–4.74)
PI = Prediction interval, based on the t distribution with 12 degrees of freedom (t0.975 = 2.1788) for total rates and with 5 degrees of freedom 
(t0.975 = 2.5706) for sex-specific rates.
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